Evidence map›Paper›PMID 34768783›Full record

ReviewInternational journal of molecular sciences2021

Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma.

Rafael Roesler, Barbara Kunzler Souza, Gustavo R Isolan

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Rafael RoeslerDepartment of Pharmacology, Institute for Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre 90050-170, Brazil.ORCID 0000-0001-6016-2261
Barbara Kunzler SouzaExperimental Research Center, Cancer and Neurobiology Laboratory, Clinical Hospital (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre 90035-003, Brazil.
Gustavo R IsolanGraduate Program in Surgery, Mackenzie Evangelical University of Paraná (FEMPAR), Curitiba 80730-000, Brazil.
Universidade Federal do Rio Grande do Sul · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 305647/2019-9Epigenica Biosciences Not applicableFundação de Amparo à Pesquisa do Estado do Rio Grande do Sul 17/2551-0001 071-0The Center for Advanced Neurology and Neurosurgery (CEANNE)-Brazil Not applicable
6 · The paper itself

Abstract

Meningioma (MGM) is the most common type of intracranial tumor in adults. The validation of novel prognostic biomarkers to better inform tumor stratification and clinical prognosis is urgently needed. Many molecular and cellular alterations have been described in MGM tumors over the past few years, providing a rational basis for the identification of biomarkers and therapeutic targets. The role of receptor tyrosine kinases (RTKs) as oncogenes, including those of the ErbB family of receptors, has been well established in several cancer types. Here, we review histological, molecular, and clinical evidence suggesting that RTKs, including the epidermal growth factor receptor (EGFR, ErbB1), as well as other members of the ErbB family, may be useful as biomarkers and therapeutic targets in MGM.

Indexed as

Biomarkers, TumorErb-b2 Receptor Tyrosine KinasesErbB ReceptorsHumansMeningiomaOncogene Proteins v-erbBPhosphorylationPrognosisReceptor Protein-Tyrosine KinasesSignal TransductionTyrosineBiomarkers, TumorEGFR protein, humanErb-b2 Receptor Tyrosine KinasesErbB ReceptorsOncogene Proteins v-erbBReceptor Protein-Tyrosine KinasesTyrosinebiomarkerepidermal growth factor receptorErbBintracranial tumormeningioma

Identifiers

PMID34768783
PMCPMC8583503
OpenAlexW3207249088

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.